A phase II study of Velcade (bortezomib-PS341) in the treatment of patients over 18 years with Ph+ (Philadelphia chromosome positive) leukemia [i.e., chronic myeloid leukaemia, acute lymphoblastic leukaemia]

Trial Profile

A phase II study of Velcade (bortezomib-PS341) in the treatment of patients over 18 years with Ph+ (Philadelphia chromosome positive) leukemia [i.e., chronic myeloid leukaemia, acute lymphoblastic leukaemia]

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Nov 2008 Status changed from recruiting to completed.
    • 23 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top